Earningsreport

Q2/2025 6/30/2025 EPS -0.300 ZacksConsensus -0.250 ActVsEst (0.050) - Miss

Relmada Therapeutics, Inc.  (RLMD) 
NASDAQ:AMEX Investor Relations: ir.relmada.com